An Intervention Study on Transcranial Photobiomodulation in Children With Attention Deficit Hyperactivity Disorder

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-18
SponsorQilu Hospital of Shandong University

About this trial

This study aims to intervene in children and adolescents with ADHD using transcranial photobiomodulation, comparing its effects on executive function at the levels of electroencephalography (EEG), eye tracking, and cognitive behavior. The goal is to identify the most effective clinical treatment strategy for ADHD patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age between 6 and 18 years;

Clinically diagnosed with ADHD by a psychiatrist;

Confirmed by the researcher (child psychiatrist) to meet the diagnostic criteria for Attention-Deficit/Hyperactivity Disorder as outlined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);

M.I.N.I. KID interview shows only ADHD, with no other comorbidities;

Disqualifiers

Diagnosis of other severe mental illnesses, such as schizophrenia or bipolar disorder;

Presence of severe physical diseases or conditions, such as significant intracranial lesions, thyroid disorders, epilepsy, congenital heart disease, severe hematologic disorders, systemic lupus erythematosus, auditory or visual impairments, etc.;

Presence of significant structural brain abnormalities on imaging studies;

Presence of severe neurological diseases with a clear family history or potential risk;

Trial design

Design model

Crossover

Treatments tested in this trial

  • tPBM(active)

    Device

    During the active stimulation condition, participants will receive a single session of tPBM intervention, lasting 12 minutes.

  • tPBM(sham)

    Device

    During the sham stimulation condition, participants will receive the same intervention with identical target areas and wavelength, but only for the first and last 30 seconds of the session.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: active stimulationActive comparator 1 intervention
Group B: sham stimulationSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

EEG(Electroencephalogram)

The Electroencephalogram was recorded while participants performed a continuous attention task. The Negative 2-Posterior Contralateral(N2pc) waveform was analyzed, and a comparison of the N2pc waveforms following true and false stimuli was made to assess the improvement of attention in participants induced by transcranial light biofeedback.

Time frame
From enrollment to the end of treatment at 3 weeks"
2

Executive Function Task

Participants completed an executive function task following active and sham stimuli to compare the effects of transcranial Photobiomodulation on the improvement of executive function in children with ADHD.

Time frame
From enrollment to the end of treatment at 3 weeks"

Secondary outcomes

1

Swanson, Nolan, and Pelham Version IV

Participants completed the Swanson, Nolan, and Pelham Version IV (SNAP-IV) scale following active and sham stimuli to compare the effects of transcranial light biofeedback on the improvement of attention and hyperactivity-impulsivity symptoms in children with ADHD.

Time frame
From enrollment to the end of treatment at 3 weeks"
2

Sleep Disturbances Scale for Children

Participants completed the Sleep Disturbances Scale for Children (SDSC) scale following active and sham stimuli to compare the effects of transcranial Photobiomodulation on the improvement of sleep symptoms in children with ADHD.

Time frame
From enrollment to the end of treatment at 3 weeks"
3

Behavior Rating Inventory of Executive Function

Participants completed the Behavior Rating Inventory of Executive Function (BRIEF) scale following active and sham stimuli to compare the effects of transcranial Photobiomodulation on the improvement of attention control, emotional regulation, and behavioral inhibition in children with ADHD.

Time frame
From enrollment to the end of treatment at 3 weeks"

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Qilu Hospital of Shandong University

Lead sponsor

Capital Medical University

Collaborator

Peking Union Medical College

Collaborator

Chinese Academy of Medical Sciences

Collaborator